Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634231 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
A Phase 1 study, sponsored by Candel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00634231 is a Phase 1 study that has completed, run by Candel Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT00634231, a Phase 1 study, has completed, sponsored by Candel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will evaluate the administration of AdV-tk followed by valacyclovir in children with malignant glioma, including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), as well as recurrent ependymomas in combination with radiation therapy. The primary objective is to determine if this approach is safe and can be effectively delivered without disturbing standard therapy.
Interventions
- RADIATION Radiation
- DRUG valacyclovir
- BIOLOGICAL AdV-tk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-10 |
| Est. Completion | 2021-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00634231
The ClinicalTrials.gov registry entry for NCT00634231 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Candel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation is the first listed.
NCT00634231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00634231 about?
NCT00634231 is a clinical study titled "A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors". This study will evaluate the administration of AdV-tk followed by valacyclovir in children with malignant glioma, including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), as well as recurrent ependymomas in combination with radiation therapy. The primary objective is to determine if ...
What is the current status of trial NCT00634231?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2010-10. Estimated completion is 2021-06.
What interventions are being tested in trial NCT00634231?
The interventions under investigation include: Radiation (RADIATION), valacyclovir (DRUG), AdV-tk (BIOLOGICAL).
Who is sponsoring clinical trial NCT00634231?
This trial is sponsored by Candel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.